Pure Global

AFIAS Anti-CCP Plus - India CDSCO Medical Device Registration

AFIAS Anti-CCP Plus is a medical device registered with India's Central Drugs Standard Control Organization (CDSCO) under UID IMP/IVD/2021/000365_c52856df9f85d0396d95b718f9f2e324_4d8288aa1f637501b65460ee3d3240af. This device is marketed under the brand name AFIAS Infliximab . The license holder is BODITECH MED INDIA PRIVATE LIMITED, and it is classified as Device Class Class B. The approving authority is CDSCO.

This page provides comprehensive regulatory information including complete registration details, license holder information, device classification, and related products. Pure Global AI offers free access to 71,807+ India medical device registrations, helping global MedTech companies identify partners, analyze markets, and discover business opportunities efficiently.

Free Database
Powered by Pure Global AI
CDSCO Registered
Class Class B
AFIAS Anti-CCP Plus
UID: IMP/IVD/2021/000365_c52856df9f85d0396d95b718f9f2e324_4d8288aa1f637501b65460ee3d3240af

Brand Name

AFIAS Infliximab

Device Class

Class B

Approving Authority

CDSCO

Product Information

AFIAS Anti-CCP Plus is a fluorescence Immunoassay (AFIAS Infliximab ) for the quantitative determination of human IgG autoantibodies to cyclic citrullinated peptides (AFIAS Infliximab ) in human whole blood/serum/plasma. It is useful as an aid in the diagnosis of rheumatoid arthritis (AFIAS Infliximab ) in combination with other clinical and laboratory findings

Pure Global
DJ Fang

DJ Fang

MedTech Regulatory Expert

Need help with 30+ markets registration?

Pricing